Skip to main content
BC Innovations
Feature Story

Now hear this

How Frequency is restoring hearing with next-generation regenerative medicine

By Lauren Martz, Senior Writer

Most regenerative medicine companies are using stem cell therapies to replace and regrow damaged tissues, but development of stem cell therapies is complicated by manufacturing and regulatory challenges. Frequency Therapeutics Inc. is creating a next generation approach to regenerative medicine that uses small molecules to reactivate a patient's dormant progenitor cells in vivo.

The newco emerged from stealth mode last week with the announcement of its new board of directors, which is headed by Chairman Marc Cohen, co-founder of Cobro Ventures, and includes serial entrepreneur and co-founder Robert Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology. The company has an undisclosed amount of financing from Cobro, and a group of angel and super angel investors.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial